First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child

Journal of Clinical Virology

Volumn 57, Issue 2, 2013, Pages 157-160

  Hakacova, Nina ^a   Klingel, Karin ^b   Kandolf, Reinhard ^b   Engdahl, Elin ^c   Fogdell Hahn, Anna ^c   Higgins, Thomas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Artesunate; Human herpesvirus 6; Left ventricular assist device; Viral myocarditis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTESUNATE; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GANCICLOVIR; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INOTROPIC AGENT; TROPONIN T; VIRUS DNA; ANTIVIRUS AGENT; ARTEMISININ DERIVATIVE;

ABSENCE OF SIDE EFFECTS; AORTOGRAPHY; ARTICLE; CARDIOMEGALY; CASE REPORT; CD3+ T LYMPHOCYTE; CHILD; CORONARY ARTERY ANOMALY; DNA SEQUENCE; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; EXPLANT; FOLLOW UP; HEART; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART VENTRICLE WALL MOTION; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMPLANTATION; IN SITU HYBRIDIZATION; LEFT VENTRICULAR ASSIST DEVICE; LUNG INFILTRATE; LYMPHOCYTIC MYOCARDITIS; MACROPHAGE; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ST SEGMENT; T WAVE INVERSION; TACHYCARDIA; TACHYPNEA; THORAX RADIOGRAPHY; TRICUSPID VALVE REGURGITATION; VIRUS LATENCY; VIRUS LOAD; VIRUS MYOCARDITIS; WEANING; DRUG EFFECTS; GENETICS; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; INFANT; MYOCARDITIS; PATHOLOGY; ROSEOLOVIRUS INFECTIONS; THERAPY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; ARTEMISININS; HEART-ASSIST DEVICES; HERPESVIRUS 6, HUMAN; HUMANS; INFANT; MYOCARDITIS; POLYMERASE CHAIN REACTION; ROSEOLOVIRUS INFECTIONS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84877004815     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.02.005     Document Type: Article

References (27)

1. Caserta M.T., Mock D.J., Dewhurst S. Human herpesvirus 6. Clin Infect Dis 2001, 33:829-833.
2. De Bolle L., Naesens L., De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005, 18:217-245.
3. Leveque N., Boulagnon C., Brasselet C., Lesaffre F., Boutolleau D., Metz D., et al. A fatal case of human herpesvirus 6 chronic myocarditis in an immunocompetent adult. J Clin Virol 2011, 52:142-145.
4. Kuhl U., Pauschinger M., Noutsias M., Seeberg B., Bock T., Lassner D., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with " idiopathic" left ventricular dysfunction. Circulation 2005, 111:887-893.
5. Yoshikawa T., Ihira M., Suzuki K., Suga S., Kito H., Iwasaki T., et al. Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J Clin Pathol 2001, 54:792-795.
6. Bonnafous P., Naesens L., Petrella S., Gautheret-Dejean A., Boutolleau D., Sougakoff W., et al. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther 2007, 12:877-888.
7. Isegawa Y., Hara J., Amo K., Osugi Y., Takemoto M., Yamanishi K., et al. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009, 44:15-19.
8. He R., Park K., Cai H., Kapoor A., Forman M., Mott B., et al. Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2012, 56:3508-3515.
9. Milbradt J., Auerochs S., Korn K., Marschall M. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J Clin Virol 2009, 46:24-28.
10. Shapira M.Y., Resnick I.B., Chou S., Neumann A.U., Lurain N.S., Stamminger T., et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46:1455-1457.
11. Kaptein S.J., Efferth T., Leis M., Rechter S., Auerochs S., Kalmer M., et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006, 69:60-69.
12. Mahrholdt H., Wagner A., Deluigi C.C., Kispert E., Hager S., Meinhardt G., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006, 114:1581-1590.
13. Pankuweit S., Klingel K. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Fail Rev 2012.
14. Pellett P.E., Ablashi D.V., Ambros P.F., Agut H., Caserta M.T., Descamps V., et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012, 22:144-155.
15. Efferth T., Marschall M., Wang X., Huong S.M., Hauber I., Olbrich A., et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 2002, 80:233-242.
16. Efferth T., Romero M.R., Wolf D.G., Stamminger T., Marin J.J., Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008, 47:804-811.
17. Wolf D.G., Shimoni A., Resnick I.B., Stamminger T., Neumann A.U., Chou S., et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011, 90:183-186.
18. Chou S., Marousek G., Auerochs S., Stamminger T., Milbradt J., Marschall M. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res 2011, 92:364-368.
19. Sellar R.S., Ward K.N., Thomson K.J., Peggs K.S. Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT. Bone Marrow Transplant 2012, 47:1482-1483.
20. He Y., Fan J., Lin H., Yang X., Ye Y., Liang L., et al. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 2011, 31:53-60.
21. Lau P.K., Woods M.L., Ratanjee S.K., John G.T. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011, 52:279.
22. Park S.J., Kushwaha S.S., McGregor C.G. State-of-the-art implantable cardiac assist device therapy for heart failure: bridge to transplant and destination therapy. Clin Pharmacol Ther 2012, 91:94-100.
23. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004, 363:9-17.
24. Ribeiro I.R., Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 1998, 58:50-53.
25. de Vries P.J., Dien T.K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996, 52:818-836.
26. Wagner S., Hofmann A., Siedle B., Terfloth L., Merfort I., Gasteiger J. Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem 2006, 49:2241-2252.
27. Gordi T., Lepist E.I. Artemisinin derivatives: toxic for laboratory animals, safe for humans?. Toxicol Lett 2004, 147:99-107.